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ARTICLE
NordicDB: a Nordic pool and portal for genome-wide
control data
Monica Leu*,1,2, Keith Humphreys1, Ida Surakka2,3, Emil Rehnberg1, Juha Muilu2, Pa¨ivi Rosenstro¨m2,
Peter Almgren4, Juha Ja¨a¨skela¨inen5, Richard P Lifton6, Kirsten Ohm Kyvik7, Jaakko Kaprio2,8,9,
Nancy L Pedersen1, Aarno Palotie2,10,11, Per Hall1, Henrik Gro¨nberg1, Leif Groop4, Leena Peltonen2,3,10,11,
Juni Palmgren1,12 and Samuli Ripatti*,2,3
A cost-efficient way to increase power in a genetic association study is to pool controls from different sources. The genotyping
effort can then be directed to large case series. The Nordic Control database, NordicDB, has been set up as a unique resource
in the Nordic area and the data are available for authorized users through the web portal (http://www.nordicdb.org). The current
version of NordicDB pools together high-density genome-wide SNP information from B5000 controls originating from Finnish,
Swedish and Danish studies and shows country-specific allele frequencies for SNP markers. The genetic homogeneity of the
samples was investigated using multidimensional scaling (MDS) analysis and pairwise allele frequency differences between the
studies. The plot of the first two MDS components showed excellent resemblance to the geographical placement of the samples,
with a clear NW–SE gradient. We advise researchers to assess the impact of population structure when incorporating NordicDB
controls in association studies. This harmonized Nordic database presents a unique genome-wide resource for future genetic
association studies in the Nordic countries.
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INTRODUCTION
Genetic association studies aim to identify variants that predict disease
susceptibility, prognosis or therapy response. Many association studies
use geographically matched cases and controls, with controls selected
and genotyped for each study. Recent successes in reusing existing
controls for newly genotyped cases1,2 indicate possibilities for design-
ing more cost-effective designs of the next generation of studies.
Pooling controls from different studies can be a cost-efficient way to
increase the power to detect or verify loci of modest effect size.
The Nordic Center of Excellence in Disease Genetics (http://
www.ncoedg.org), formed by the Joint Committee of the Nordic
Medical Research Councils, the Nordic Council of Ministers and the
Nordic Research Board, announces the release of the Nordic Control
database, ‘NordicDB’, providing high-density genome-wide SNP
information for B5000 healthy individuals. At present, NordicDB
contains randomly ascertained samples from Finland, Sweden and
Denmark. The portal (http://www.nordicdb.org), which is under
continual development, provides population statistics and
web-based tools for efficient use of this resource. Thus, for example,
the portal describes quality control (QC) and imputation methods and
provides imputed genotype probabilities (HapMap 3 SNPs). This paper
introduces the NordicDB and its first release of the imputed data.
MATERIALS AND METHODS
The Nordic Control Database, NordicDB
NordicDB pools together samples from Finnish, Swedish and Danish studies.
The selection of studies came from PIs at NCoEDG sites. These samples are
individuals chosen to be controls in the original case–control studies. Table 1
presents the contributing studies with number of samples and genotyped SNPs,
genotyping platform, sample characteristics, sampling location and reference
to papers describing the respective studies in more detail.
When constructing NordicDB, each data set was individually subjected to
unified genotype QC measures. Briefly, SNPs were aligned to top strand and
updated to build 36. We removed markers with ambiguous allele coding, and
individuals and markers with45% of data missing, as well as individuals with
sex inconsistencies between the genotype data and the indicated sex. First- or
second-degree relatives were filtered out on the basis of IBD values 40.2. On
the basis of QC, on average, o3% of markers and o4% of individuals were
excluded from the data sets.
Database and portal
The relational database and the web-based data management application
were built using the Molgenis application generator (Molgenis; http://molgenis.
sourceforge.net/).10 The database contains information and statistics on
samples, markers, genotype data releases and sampling location. The sample
identifiers were anonymized for the purpose of this database and cannot be
linked to the original study identifiers. All SNPs are on top strand alignment and
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their physical positions are on build 36. Individual level data can be accessed
through an application process using the application form available on the portal
(http://www.nordicdb.org/database/Access.html). Applications will be reviewed
by the Nordic Center of Excellence Data Review Board (http://www.nordicdb.
org/drb) consisting of the PIs of the studies in NordicDB. At the time of
preparing this paper, the Data Review Board members were affiliated to the Lund
University (Sweden), Karolinska Institutet (Sweden), Sanger Institute (UK) and
the University of Tartu (Estonia). The potential user has to specify the data set(s)
that he would be requesting and a brief description of the proposed research use
of the requested data. The user must also offer the following assurances that:
 The data will only be used only for approved research, as follows:
 As control data for case–control study design or as population set for
population genetics analyses
 As example data for software algorithm development:
1. Addressing challenges associated with the analysis of sets of genotypic data.
2. Detecting differences in allele frequency based on phenotypic data.
3. Development of advanced analysis tools for the genetic community.
 Data confidentiality will be strictly protected.
 All applicable laws, local institutional policies and terms and procedures
specific to the study’s data access policy for handling anonymized popula-
tion control data will be followed.
 No attempts will be made to identify individual study participants from
whom genotype data were obtained using genotype data or by trying to
combine genotype data with any other information.
 No information regarding the obtained control data set will be shared with
or sold to third parties.
 The contributing investigator(s) who conducted the original study and
the funding organizations involved in supporting the original study will
be acknowledged in publications resulting from the analysis of those data.
The FIMM Technology Center (FTC) will provide information regarding
which investigators should be acknowledged.
 An annual report on research progress and publications, in which control
data have been used, will be submitted to the FTC.
Finally, the control data use agreement must be cosigned by a group/
department/institute leader, who represents the institution for which the
applicant works. As data access policies are still being developed, these require-
ments and policies may change from what is described herein without notice.
Some data sets will require the original contributing investigator to be contacted
and getting his approval in addition to application approval by the FTC.
The data can be also accessed through the European Genotype Archive
(http://www.ebi.ac.uk/ega). In particular, for each sample, researchers will be
able to obtain genotype data and an indication of the study from which
genotypes originate. As samples from different studies have been genotyped
with different technology and SNP locations, we also provide imputed
genotypes (see the ‘Imputed data’ section).
Population structure in the Nordic Control database
Population structure can be measured in terms of differences in allele
frequencies and linkage disequilibrium (LD) patterns between sub-populations
due to systematic ancestry differences. In genetic association studies, when
there are differences in allele frequencies between individuals with different
disease/trait status due to population structure sampling differences by disease
status, the false-positive error rate is inflated.11,12 Therefore, population
structure must be considered carefully when pooling controls that originate
from different populations.13 Recent studies have shown that, even for small
isolated populations or for populations within restricted areas, stratification
should be evaluated and accounted for when assessing genetic association.6,14
As the NordicDB samples were collected from different Nordic countries, we
investigated potential layers of stratification through the multidimensional
scaling (MDS) analysis in PLINK.15 Before performing the MDS analysis, we
removed non-autosomal SNPs, SNPs in known inverted regions,16 SNPs with
MAF o0.01 and SNPs that failed the Hardy–Weinberg equilibrium test at the
significance threshold of 1e-06. Individuals identified as outliers based on the
inbreeding coefficient were also excluded (Supplementary material available at
http://nordicdb.org/database/Data.html). The MDS analysis was based on SNPs
which were common across platforms (B45k SNPs). From the restricted SNP
set, only SNPs and individuals witho5% missingness were included and only
SNPs with low LD.13 To prune SNPs in LD, the pairwise genotypic correlation
was calculated between all SNPs within windows of 20 SNPs and 1 SNP was
excluded from each pair if the LD was found40.1. A forward shift of five SNPs
was assumed between windows. For the purpose of the MDS assessment, a
Finnish reference data set was included. This consists of 81 individuals, 40
individuals collected from the capital area, representing genetically general
population, and 41 individuals from a Finnish isolate, late-settlement area
(LSFIN, described elsewhere17,18). SNPs from the Illumina Human 1M-Duo
chip (Illumina, San Diego, CA, USA) and the Affymetrix Genome-Wide
Human SNP Array 6.0 chip (Affymetrix, Santa Clara, CA, USA) were
Table 1 GWAS studies contributing controls to the Nordic Control Database
Study
Number of
samples
Number of
SNPs
Genotyping
platform
Sampling
location Sample characteristics
Cancer Prostate in
Sweden (CAPS) 13
502 492 555 Affymetrix 550K Central and
Northern Sweden
Males; mean age: 66.4±7.1 years
Cancer Prostate in
Sweden (CAPS) 23
519 440 092 Affymetrix 5.0 Central and
Northern Sweden
Males; mean age: 66.4±7.1 years
Cancer And Hormonal
Replacement
in Sweden (CAHRES)4
764 561 274 Illumina HumanHap-550-v3 Sweden Females; mean age: 63±6.5 years
Diabetes Genetics
Initiative (DGI)5
1467 496 963 Affymetrix 550K Southern Sweden and
Western Finland (Botnia)
654 males/701 females; mean age:
58.3±6.5 years (SWE);
59±10 years (FIN)
SGENE and MS6 241 318 212//
314 691
Illumina HumanHap-300-v2.0/v1.0// Helsinki region 148 males/93 females; mean age
43.1±11 years (SGENE)
Aneurysm study7 697 341 389 Illumina HumanCNV-370-v1.0 Kupio and Helsinki 304 males/393 females; mean age
58.1±18.66 years
GenomEUtwin-DK8,9 173 318 212 Illumina HumanHap-300-v2.0 Denmark Females; age range 20–80 years
GenomEUtwin-SWE8,9 302 318 212 Illumina HumanHap-300-v2.0 Sweden Females; age range 20–80 years
GenomEUtwin-FIN8,9 157 318 212 Illumina HumanHap-300-v2.0 Finland 13 males/144 females;
age range 20–80 years
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genotyped, resulting in 1 163 280 SNPs after applying QC. The haplotypes in
this data set were phased similarly to the HapMap 3 CEU samples (individuals
with NW European ancestry) and Tuscany in Italy (TSI). Figure 1a shows the
first two axes of genetic variation in NordicDB, CEU HapMap 3 data and the
Finnish reference set. The analysis was based on 4809 samples: 2458 Swedish,
2082 Finnish, 161 Danish and 108 from CEU. The plot of the first two MDS
components shows excellent resemblance to the geographical placement of the
samples (Figure 1b), with a clear NW–SE gradient. To validate the SNP set used
in the MDS analysis, we compared patterns of variation based on all available
SNPs and on the restricted set, using two studies genotyped on the same chip
(CAPS and DGI). The results were similar (data not shown).
Table 2 shows summary statistics for allele frequency differences and
similarities between study populations. We calculated pairwise FST values using
Weir and Cockerham’s approach implemented in the R package Geneland19
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Figure 1 (a) Top axes of genetic variation in the Nordic Control Database, NordicDB (4620 samples) contrasted with the HapMap CEU (108 samples)
and a Finnish HapMap reference population (81 samples). The MDS analysis was performed on B45 000 SNPs that were common between genotyping
platforms. The controls are part of the following studies: Cancer Prostate in Sweden (CAPS) 1 and 2, Cancer and Hormonal Replacement in Sweden
(CAHRES), Diabetes Genetics Initiative in Western Finland and Southern Sweden (DGI-FIN and DGI-SWE), SGENE and MS in the Helsinki region, Aneurysm
study in the Helsinki region, GenomEUtwin Denmark (GenomEUtwin-DK), GenomEUtwin Sweden (GenomEUtwin-SWE) and GenomEUtwin Finland
(GenomEUtwin-FIN). (b) Geographical map of Scandinavia with three countries highlighted to show the origin of the samples in panel a: Finland (red),
Sweden (green) and Denmark (yellow).
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(see http://www.nordicdb.org). The largest differences were those between
Finnish and Swedish studies, with magnitude varying according to the location
of the Finnish study.
Imputed data
The limited overlap of SNPs across genotyping platforms and chips is a key
issue for NordicDB to address. The Illumina (http://www.illumina.com) and
Affymetrix (http://affymetrix.com/index.affx) platforms, which differ in terms
of genomic coverage, call rate and accuracy, array processing time and ease of
use, typically have an SNP overlap of B10%. Thus, to provide a harmonized
SNP set, imputation of non-overlapping SNPs is required. We use Impute
software (University of Oxford, Oxford, UK; https://mathgen.stats.ox.ac.uk/
impute/impute.html)20 to impute genotypes of the individuals in NordicDB
against a common reference set. Choice of the reference population was based
on comparing accuracy of imputing in three data sets (namely CAPS1, CAPS2
and CAHRES) using different populations, CEU HapMap 2, CEU Hapmap 3,
and the combined HapMap 3 European populations CEU and TSI, in a subset
of SNPs from chromosomes 21 and 22. Genotypes of directly typed SNPs were
compared with their calls after imputing. The subset of SNPs was chosen by
first selecting all SNPs that were common to the genotyping platforms that
were used in the three studies (see Table 1) and then removing a minimum
number of them such that the maximum pairwise r2 value was 0.2, among the
remaining
SNPs. Genotypes for SNPs in the selected subset were imputed using geno-
types of all other typed SNPs on chromosomes 21 and 22. To assess imputation
accuracy, we calculated the root mean square error of prediction (RMSEP)
over SNPs and individuals. Writing yki to denote the observed genotype
for SNP k of individual i, and pjki to denote the posterior probability of
genotype jA{0,1,2}, obtained from IMPUTE, for SNP k, individual i, RMSEP
was calculated as
RMSEP ¼ 1
NK
XN
i¼1
XK
k¼1
X2
j¼0
pjki yki  jð Þ2 ð1Þ
where K is the number of SNPs in the subset of imputed SNPs and N the
number of individuals in the data set. Accurate imputation results are reflected
by low RMSEP values. Without exception, lowest RMSEP values were achieved
for the CEU and TSI populations combined (Table 3). Therefore, we used this
reference population to impute all data sets in the database. The imputation
procedure is described in more detail on the portal, (http://www.nordicdb.org)
in which information on how to download imputed data is also provided.
Table 4 presents a summary of imputation accuracy for the Nordic Control
database, based on those SNPs that were genotyped in at least 90% of
the individuals in the originating study. For chromosome 15, a minimum
of 85% of SNPs were called after the imputation at a threshold of 0.9, with
a concordance rate of B99% (Table 4, last column).
DISCUSSION
We have described an open resource (NordicDB) that pools GWAS
samples from the Nordic countries. With population substructure
present across the Nordic populations,6,14 there is an obvious need to
assess its impact when using NordicDB with a new study population
of cases. In dealing with substructure, one should consider adjustment
for the main axes of genetic variation21 or selecting a subset of controls
that are ancestrally compatible with the cases. An obvious limitation of
the Nordic DB is that it includes no environmental variables, and
therefore users will not be able to adjust for environmental confoun-
ders in performing their own association analyses.
The samples in NordicDB were genotyped with different technol-
ogies. This called for harmonizing the QC measures and for imputing
the non-overlapping markers using the publicly available LD data
from HapMap 3. This allows scientists interested in studying Nordic
populations to use their preferred platform to genotype new cases and
use NordicDB to pick readily genotyped controls for their studies.
Table 2 Pairwise FST values for data sets in the Nordic Control Database
Study a
CAPS
1 and 2 CAHRES DGI-FIN DGI-SWE
SGENE
and MS Aneurysm
Genom
EUtwin-DK
Genom
EUtwin-SWE
Genom
EUtwin-FIN
CEU
HapMap 3b
Finnish
reference
CAPS 1 and 2 — 0 0.001 0 0.004 0.004 0 0 0.003 0.001 0.006
CAHRES — 0.001 0 0.004 0.004 0 0 0.004 0 0.006
DGI-FIN — 0.001 0.002 0.002 0.001 0.001 0.001 0.002 0.004
DGI-SWE — 0.006 0.005 0 0 0.004 0.001 0.005
SGENE and MS — 0.001 0.007 0.005 0.001 0.007 0.001
Aneurysm — 0.005 0.004 0 0.006 0.001
Genom EUtwin-DK — 0.001 0.004 0.001 0.006
Genom EUtwin-SWE — 0.003 0.001 0.005
Genom EUtwin-FIN — 0.005 0.001
CEU HapMap 3 — 0.007
Finnish reference —
To easily distinguish FST values between countries, the following text formatting was used: Finland–Finland: roman, Sweden–Sweden: bold, Sweden–Finland: italics, Sweden–Denmark: underline,
Denmark–Finland: bold italics.
Calculations were based on B2500 SNPs, chosen with a low LD between each other (pairwise LD values were calculated within windows of 50 SNPs and 1 SNP was excluded from each pair if LD
was found 40.006. A forward shift of five SNPs was used between windows.
aMore complete names of the studies are provided in Table 1.
bAll the values in this column pretain to general European reference population, thus neither Finnish, Swedish or Danish.
Table 3 Comparison of imputation accuracy for three reference
populationsa
Study/reference population CEU HapMap 2 CEU HapMap 3 CEU+TSI HapMap 3
Cancer Prostate in Sweden (CAPS) 1
Chr 21 0.159 0.151 0.144
Chr 22 0.179 0.180 0.175
Cancer Prostate in Sweden (CAPS) 2
Chr 21 0.164 0.151 0.144
Chr 22 0.194 0.189 0.187
Cancer And Hormonal Replacement in Sweden (CAHRES)
Chr 21 0.079 0.069 0.064
Chr 22 0.081 0.073 0.068
aMean prediction error (RMSEP values) over SNPs and individuals. Calculations are based on
overlapping SNPs between platforms.
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Table 4 Imputation accuracy for the Nordic Control Databasea
Study Number of imputed genotypes b % Called at 0.9 threshold % Concordance c
Cancer Prostate in Sweden (CAPS) 1 and 23 9 311 088 89.46 98.41
Cancer And Hormonal Replacement in Sweden (CAHRES)4 11 134 120 92.76 99.02
Diabetes Genetics Initiative (DGI)5 12 787 169 89.45 98.35
SGENE and MS6 1 721 751 84.99 98.04
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GenomEUtwin-SWE8,9 2 453 897 86.35 98.43
GenomEUtwin-FIN8,9 1 245 029 85.47 98.11
aCalculations are based on chromosome 15.
bCalculated as the number of typed SNPs (in at least 90% of the individuals) multiplied by the number of individuals in the data set.
cThe concordance is based on the SNPs in the second column that were called after the imputation using a 0.9 threshold.
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